Component

Insulin-stimulated glucose disposal

Insulin-stimulated glucose disposal. Species, exposure and limitations are retained in each linked claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. The exploratory clamp trial found a 27% greater change in glucose-disposal clearance versus placebo after pooling ALA groups.

    Lipoic acid → Insulin-stimulated glucose disposal source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/ala-research/10468203.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "06f09aa0ad208b561612e62d5ce388b90205f8e767f1cf96545162ec2bf24a9a", "start_char": 0, "end_char": 2007, "text_sha256": "06f09aa0ad208b561612e62d5ce388b90205f8e767f1cf96545162ec2bf24a9a"}
    experimental_model
    Exploratory randomized placebo-controlled glucose-clamp pilot
    exposure
    600, 1200 or 1800 mg/day oral ALA for four weeks
    limitations
    Active doses were pooled after no dose effect was detected; exploratory design and surrogate outcome, not long-term diabetes complications.
    nutrient_topic
    Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
    organism
    Human
    plain_language
    Insulin sensitivity improved in this small short-term experiment.
    primary_references
    [ala-p10468203] Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. (1999). https://pubmed.ncbi.nlm.nih.gov/10468203/ DOI: 10.1016/s0891-5849(99)00089-1
    tissue_or_cell_type
    74 participants with type 2 diabetes

    Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1196–1207

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Exploratory randomized placebo-controlled glucose-clamp pilot · source_derived_draft · unverified_draft

    ### ala-clamp-insulin-sensitivity The exploratory clamp trial found a 27% greater change in glucose-disposal clearance versus placebo after pooling ALA groups. Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: Insulin sensitivity improved in this small short-term experiment. organism: Human tissue_or_cell_type: 74 participants with type 2 diabetes experimental_model: Exploratory randomized placebo-controlled glucose-clamp pilot limitations: Active doses were pooled after no dose effect was detected; exploratory design and surrogate outcome, not long-term diabetes complications. exposure: 600, 1200 or 1800 mg/day oral ALA for four weeks evidence_span: {"source_cache": "artifacts/ala-research/10468203.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "06f09aa0ad208b561612e62d5ce388b90205f8e767f1cf96545162ec2bf24a9a", "start_char": 0, "end_char": 2007, "text_sha256": "06f09aa0ad208b561612e62d5ce388b90205f8e767f1cf96545162ec2bf24a9a"} [ala-p10468203] Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. (1999). https://pubmed.ncbi.nlm.nih.gov/10468203/ DOI: 10.1016/s0891-5849(99)00089-1
    Complete structured claim and evidence

  2. The between-group difference in clamp glucose disposal was not statistically significant, with P=0.063.

    Berberine → Insulin-stimulated glucose disposal source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/berberine-research/18397984.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0711d6853427d4b78af4704fd7630e08ed0f83d599311156dbc8570efd88dce2", "start_char": 0, "end_char": 1715, "text_sha256": "0711d6853427d4b78af4704fd7630e08ed0f83d599311156dbc8570efd88dce2"}
    experimental_model
    Randomized placebo-controlled clinical trial
    exposure
    Berberine 1 g/day for three months
    limitations
    Short trial with surrogate endpoints. Within-arm clamp improvement was not statistically significant versus placebo; lower glucose does not identify one causal enzyme.
    nutrient_topic
    Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine
    organism
    116 people with type 2 diabetes and dyslipidemia
    plain_language
    A positive change within one group did not establish superiority on this insulin-sensitivity endpoint.
    primary_references
    [berberine-p18397984] Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. (2008). https://pubmed.ncbi.nlm.nih.gov/18397984/ DOI: 10.1210/jc.2007-2404
    tissue_or_cell_type
    Glycemic markers, lipids and insulin sensitivity

    Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 1208–1219

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized placebo-controlled clinical trial · source_derived_draft · unverified_draft

    ### berberine-diabetes-clamp-null The between-group difference in clamp glucose disposal was not statistically significant, with P=0.063. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: A positive change within one group did not establish superiority on this insulin-sensitivity endpoint. organism: 116 people with type 2 diabetes and dyslipidemia tissue_or_cell_type: Glycemic markers, lipids and insulin sensitivity experimental_model: Randomized placebo-controlled clinical trial limitations: Short trial with surrogate endpoints. Within-arm clamp improvement was not statistically significant versus placebo; lower glucose does not identify one causal enzyme. exposure: Berberine 1 g/day for three months evidence_span: {"source_cache": "artifacts/berberine-research/18397984.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0711d6853427d4b78af4704fd7630e08ed0f83d599311156dbc8570efd88dce2", "start_char": 0, "end_char": 1715, "text_sha256": "0711d6853427d4b78af4704fd7630e08ed0f83d599311156dbc8570efd88dce2"} [berberine-p18397984] Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. (2008). https://pubmed.ncbi.nlm.nih.gov/18397984/ DOI: 10.1210/jc.2007-2404
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards